DUBLIN, March 1, 2018 /PRNewswire/ -- Endo
International plc (NASDAQ: ENDP) today announced that its
subsidiaries, Par Pharmaceutical, Inc. and Par Sterile Products,
LLC (Par), have obtained a preliminary injunction preventing QuVa
Pharma, Inc. (QuVa) from marketing and releasing its planned
vasopressin product that would compete with Par's Vasostrict®, the
first and only vasopressin injection, USP, product approved by the
U.S. Food and Drug Administration. The preliminary
injunction, issued today by the Hon. Brian
R. Martinotti, U.S. District Judge, is effective through the
conclusion of a trial, which has not yet been scheduled.
In August 2017, Par filed a
complaint against QuVa and several individual defendants in the
U.S. District Court for the District of New Jersey (Case No. 17-6115) alleging, among
other claims, the misappropriation of Par's trade secrets by the
defendants in connection with QuVa's development of a bulk
compounded vasopressin product.
"Endo embraces principles of fair competition. In fact,
our competitors keep us striving to improve our products and
services. That said, fair competition does not extend to the
misappropriation of our valuable information. We initiated
this litigation because we have a responsibility to protect our
Company and prevent other parties from obtaining an improper and
unfair advantage in the marketplace," said Matthew J. Maletta, Executive Vice President and
Chief Legal Officer of Endo. "We look forward to pursuing
this case through trial where we will seek permanent injunctive
relief, together with the recovery of all appropriate damages from
QuVa, the individual defendants and potentially other parties not
yet named in the litigation."
About Endo International plc
Endo International plc (NASDAQ: ENDP) is a highly focused
generics and specialty branded pharmaceutical company delivering
quality medicines to patients in need through excellence in
development, manufacturing and commercialization. Endo has global
headquarters in Dublin, Ireland,
and U.S. headquarters in Malvern,
PA. Learn more at www.endo.com.
Cautionary Note Regarding Forward-Looking Statements
Certain information in this press release may be considered
"forward-looking statements," including, but not limited to, the
statements by Mr. Maletta. All forward-looking statements in this
press release reflect Endo's current expectations of future events
based on information available to Endo as of the date of this press
release. If underlying assumptions prove inaccurate or unknown
risks or uncertainties materialize, actual results could vary
materially from Endo's expectations and projections.
Risks and uncertainties include, among other things, general
industry and market conditions; technological advances and patents
attained by competitors; challenges inherent in the research and
development and regulatory processes, including regulatory
decisions, product recalls, withdrawals and other unusual items;
challenges related to product marketing, such as the
unpredictability of market acceptance for new products and/or the
acceptance of new indications for such products; inconsistency of
treatment results among patients; potential difficulties in
manufacturing; the outcome of litigation, settlement discussions,
negotiations or other adverse proceedings; general economic
conditions; and governmental laws and regulations affecting
domestic and foreign operations. Endo expressly disclaims any
intent or obligation to update these forward-looking statements
except as required by law. Additional information concerning these
and other risk factors can be found in Endo's periodic reports
filed with the U.S. Securities and Exchange Commission and in
Canada on the System for
Electronic Data Analysis and Retrieval ("SEDAR"), including current
reports on Form 8-K, quarterly reports on Form 10-Q and annual
reports on Form 10-K.